Gurugram, 21 February 2025: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) today announced that it has signed a Business Transfer Agreement to acquire the India business of Resilient Cosmeceuticals Private Limited for a cash consideration of Rs 24 Crores, to be funded from internal accruals. The Company had a cash balance of Rs 132 Crores as on December 31, 2024.
The transaction is subject to customary closing conditions and is expected to close within 45 days.
Strategic Rationale
About Resilient
Commenting on the acquisition, Mr. Manish Gupta, Managing Director stated "This acquisition is a strategic move in Jagsonpal's growth journey, reinforcing our commitment to scaling operations and enhancing our market presence in our focus therapies, leveraging the surplus cash generated from operations.
The acquired business is complementary to Jagsonpal's existing portfolio, and we are confident that it will deliver long-term value to all stakeholders."
IncredMAPE were the transaction advisor to Resilient while ThinkLaw advocates were the legal advisor for Jagsonpal.
ABOUT JAGSONPAL PHARMACEUTICALS LIMITED
Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over four decades in the Indian pharmaceutical market.
The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, Dermatology and Child-care segments. Over the years, the Company has successfully built multiple brands that today hold market-leading positions in their respective segments. It has created a strong niche for itself with 20+ brands amongst Top 5 brands in the molecule category, extensive pan-India presence and an experienced sales team of over 900 professionals.
The company is listed on the National Stock Exchange Limited (JAGSNPHARM) and Bombay Stock Exchange (Scrip code: 507789) and is headquartered in Delhi.